Article: Nicotinamide Riboside Reverses Metabolic Dysfunction in Werner's Syndrome: Preclinical Findings

PrevNext
Metabolic Health Orphan Disease Preclinical

Nicotinamide Riboside Reverses Metabolic Dysfunction in Werner's Syndrome: Preclinical Findings

Synopsis

Werner syndrome (WS) features premature aging and metabolic dysfunction, yet mechanisms remain unclear. This study found that loss of the WRN protein accelerates early fat cell formation in both stem cells and zebrafish, partly through upregulation of SMARCA5, which regulates gene activity. Restoring WRN normalized SMARCA5 levels and fat cell development. Importantly, treatment with the NAD+ precursor nicotinamide riboside (NR) improved fat metabolism in both models, suggesting NR could help correct metabolic dysfunction in WS and potentially other aging-related conditions.

Journal

Cell & Bioscience

Share

Read more

Neurological Health

Nicotinamide Riboside Boosts NAD+, to Reduce Sleep Need and Support Brain Energy: Preclinical Findings

SynopsisNon-rapid eye movement sleep (NREMS) is linked to lower brain glucose use, which slows metabolic reactions involving NAD+. This study tested whether boosting NAD+ with nicotinamide riboside...

Read more
Cardiovascular Disease

Nicotinamide Riboside Reverses Pulmonary Hypertension: Preclinical Findings

Synopsis Pulmonary hypertension (PH) is a deadly lung vascular disease caused by endothelial dysfunction and vascular remodeling that strain the heart. This study identified Sirtuin 7 (SIRT7)—a NA...

Read more